Alto Nears Data on First-of-its-Kind Schizophrenia Cognitive Drug

MOUNTAIN VIEW, CA – February 13, 2026 – Alto Neuroscience has reached a critical milestone in the quest for a treatment for one of the most challenging aspects of schizophrenia, announcing the completion of patient enrollment in its Phase 2 study of ALTO-101. The drug, delivered via a novel skin patch, targets the debilitating cognitive impairment that affects nearly all individuals with the disorder, a condition for which no approved pharmacological treatment currently exists.

The completion of enrollment for 83 patients across 13 U.S. sites moves the clinical-stage biopharmaceutical company (NYSE: ANRO) one step closer to a highly anticipated data readout, expected around the end of the first quarter. This data will be pivotal in determining the future of ALTO-101 and could represent a watershed moment for millions of patients whose daily functioning is severely hampered by cognitive deficits.

"This milestone brings us closer to potentially delivering a first-of-its-kind treatment for the millions of patients suffering from the debilitating cognitive effects of schizophrenia," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience, in a statement. The company's confidence is bolstered by baseline study results that have already replicated findings from three independent datasets, reinforcing the scientific foundation of their approach.

The Unseen Struggle of Cognitive Impairment

While schizophrenia is often associated with symptoms like hallucinations and delusions, a more pervasive and disabling feature is the cognitive decline that accompanies it. Known as Cognitive Impairment Associated with Schizophrenia (CIAS), this condition erodes a person's memory, attention, processing speed, and executive function. These are the mental tools essential for navigating daily life—from managing finances and maintaining employment to sustaining social relationships.

For decades, the focus of treatment has been on antipsychotic medications that, while effective for psychotic symptoms, have shown minimal to no benefit for CIAS. This has left a profound unmet medical need. An estimated 98% of individuals with schizophrenia experience some level of cognitive impairment, which is a primary driver of long-term disability and a major barrier to recovery and independent living. The inability to find an effective treatment has been a long-standing failure in psychiatric medicine, leaving patients and their families to manage these debilitating symptoms with limited support from cognitive remediation therapies.

The impact on quality of life is immense. The subtle but persistent struggle with tasks requiring focus and problem-solving can lead to social withdrawal, unemployment, and a deep sense of frustration, contributing to the high rates of long-term functional problems seen in this population.

A Two-Pronged Attack on a Historic Problem

Alto Neuroscience's approach with ALTO-101 is notable for its two-pronged strategy to overcome historical hurdles in developing a CIAS drug. The first innovation lies in the drug's class and delivery method. ALTO-101 is a phosphodiesterase-4 (PDE4) inhibitor, a class of molecules known to regulate a key messenger in the brain involved in learning and memory. Preclinical studies have long suggested that inhibiting PDE4 could enhance cognition. However, previous attempts to develop oral PDE4 inhibitors for central nervous system disorders were derailed by severe gastrointestinal side effects, including nausea and vomiting, which made the drugs intolerable at effective doses.

To circumvent this, Alto has partnered with MEDRx to develop a proprietary transdermal delivery system (TDS)—a skin patch. This method allows ALTO-101 to be absorbed directly into the bloodstream, bypassing the gastrointestinal tract and mitigating the side effects that plagued its predecessors. The goal is to provide a steady, therapeutic concentration of the drug in the brain, a feat that has proven elusive for oral versions.

The second prong of Alto's strategy is its 'Precision Psychiatry Platform™'. Instead of a one-size-fits-all approach, the company is using objective, brain-based biomarkers to identify patients most likely to benefit from the treatment. The Phase 2 trial's primary endpoint is not a subjective rating scale but a direct measure of brain activity: theta-band inter-trial coherence (ITC), captured via electroencephalography (EEG). Research, including Alto's own replication studies, has shown a strong correlation between reduced theta ITC and the slower cognitive processing speed seen in CIAS. By selecting patients with clear deficits in this biomarker, Alto aims to increase the chances of detecting a clear treatment effect.

High-Stakes Data and a Cautious Market

The upcoming topline data from the Phase 2 trial represents a high-stakes moment for Alto Neuroscience. The U.S. Food and Drug Administration (FDA) has already granted ALTO-101 Fast Track Designation, a status that acknowledges the drug's potential to address a serious, unmet medical need and facilitates its development and review. A positive result would not only validate the company's precision psychiatry approach but could also send its stock soaring and position it as a leader in a potentially vast market.

Analysts have maintained a largely positive outlook on the company, with a consensus "Strong Buy" rating and price targets suggesting significant upside. This optimism is rooted in the innovative science and the enormous commercial opportunity a successful CIAS drug would represent. However, the biopharmaceutical industry is fraught with risk, and investor sentiment remains sensitive. A recent setback with another of the company's candidates, ALTO-100 for major depressive disorder, serves as a reminder of the inherent uncertainties in clinical development.

The randomized, double-blind, placebo-controlled crossover design of the ALTO-101 study is intended to maximize its statistical power, allowing each patient to serve as their own control. With the study powered to detect even a modest effect size, the neuroscience and investment communities will be watching closely as the end of the quarter approaches. A success could finally bring a tangible pharmacological hope to patients and families who have long waited for a breakthrough in the cognitive battle against schizophrenia.